132 related articles for article (PubMed ID: 11831537)
1. A simplified method for detecting isoniazid compliance in patients receiving antituberculosis chemotherapy.
Hashiguchi M; Ohno K; Sakuma A; Hino F; Tanaka T; Ohtsuji M; Matsumoto N; Yanase K; Urae A; Hosogai Y; Sato N; Yazaki A; Matsuda K; Yamazaki K; Rikihisa T
J Clin Pharmacol; 2002 Feb; 42(2):151-6. PubMed ID: 11831537
[TBL] [Abstract][Full Text] [Related]
2. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.
Chen B; Li JH; Xu YM; Wang J; Cao XM
Clin Chim Acta; 2006 Mar; 365(1-2):104-8. PubMed ID: 16182272
[TBL] [Abstract][Full Text] [Related]
3. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
Kita T; Tanigawara Y; Chikazawa S; Hatanaka H; Sakaeda T; Komada F; Iwakawa S; Okumura K
Biol Pharm Bull; 2001 May; 24(5):544-9. PubMed ID: 11379777
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Amlabu V; Mulligan C; Jele N; Evans A; Gray D; Zar HJ; McIlleron H; Smith P
Int J Tuberc Lung Dis; 2014 May; 18(5):528-30. PubMed ID: 24903787
[TBL] [Abstract][Full Text] [Related]
5. Solid-phase extraction and HPTLC determination of isoniazid and acetylisoniazid in serum. Comparison with HPLC.
Guermouche S; Guermouche MH
J Chromatogr Sci; 2004; 42(5):250-3. PubMed ID: 15189597
[TBL] [Abstract][Full Text] [Related]
6. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
Zabost A; Brzezińska S; Kozińska M; Błachnio M; Jagodziński J; Zwolska Z; Augustynowicz-Kopeć E
Biomed Res Int; 2013; 2013():853602. PubMed ID: 24383060
[TBL] [Abstract][Full Text] [Related]
7. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.
Donald PR; Parkin DP; Seifart HI; Schaaf HS; van Helden PD; Werely CJ; Sirgel FA; Venter A; Maritz JS
Eur J Clin Pharmacol; 2007 Jul; 63(7):633-9. PubMed ID: 17505821
[TBL] [Abstract][Full Text] [Related]
8. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects.
Bing C; Xiaomeia C; Jinhenga L
Drug Metabol Drug Interact; 2011; 26(3):113-8. PubMed ID: 21980963
[TBL] [Abstract][Full Text] [Related]
9. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.
Szakacs TA; Wilson D; Cameron DW; Clark M; Kocheleff P; Muller FJ; McCarthy AE
BMC Infect Dis; 2006 Jun; 6():97. PubMed ID: 16772037
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.
Chen B; Shi HQ; Feng MR; Wang XH; Cao XM; Cai WM
Front Pharmacol; 2022; 13():932686. PubMed ID: 35928262
[No Abstract] [Full Text] [Related]
11. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.
Aït Moussa L; Khassouani CE; Hüe B; Jana M; Bégaud B; Soulaymani R
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):548-53. PubMed ID: 12503812
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs.
Ellard GA; Jenner PJ; Downs PA
Br J Clin Pharmacol; 1980 Oct; 10(4):369-81. PubMed ID: 7448108
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen.
Seth V; Seth SD; Beotra A; Semwal OP; D'monty V; Mukhopadhya S
Indian Pediatr; 1994 Mar; 31(3):279-85. PubMed ID: 7896362
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.
Seng KY; Hee KH; Soon GH; Chew N; Khoo SH; Lee LS
Antimicrob Agents Chemother; 2015 Nov; 59(11):6791-9. PubMed ID: 26282412
[TBL] [Abstract][Full Text] [Related]
15. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
[TBL] [Abstract][Full Text] [Related]
16. Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD
Zhu J; Lu J; Tung HC; Liu K; Li J; Grant DM; Xie W; Ma X
Drug Metab Dispos; 2020 Dec; 48(12):1372-1379. PubMed ID: 33020065
[TBL] [Abstract][Full Text] [Related]
17. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
Cordes H; Thiel C; Aschmann HE; Baier V; Blank LM; Kuepfer L
Antimicrob Agents Chemother; 2016 Oct; 60(10):6134-45. PubMed ID: 27480867
[TBL] [Abstract][Full Text] [Related]
18. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia.
Fredj NB; Romdhane HB; Woillard JB; Chickaid M; Fadhel NB; Chadly Z; Chaabane A; Boughattas N; Aouam K
Int J Infect Dis; 2021 Mar; 104():562-567. PubMed ID: 33476758
[TBL] [Abstract][Full Text] [Related]
20. A Rapid Pharmacogenomic Assay to Detect
Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
